Bacchus gets US nod for thrombus drug delivery:
This article was originally published in Clinica
Executive Summary
Bacchus Vascular has gained FDA 510(k) clearance to sell in the US its Trellis infusion system, which facilitates the delivery of drugs, including thrombolytic agents, into the peripheral vasculature. The catheter-based drug delivery system, which was cleared for sale in Europe earlier this month (see Clinica, No 996, p 20), allows doctors to treat difficult areas of vascular occlusion and promises safety advantages, time savings and improved outcomes in thrombus management, says the Santa Clara, California firm.